Journal of Medicinal Chemistry · 2003 · 119 citations · 11 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignStructural BiologyStructure-activity RelationshipsEnzyme InhibitionIntermolecular ForcesLigand BindingProtein StructureStructure-activity Relationship AnalysisElectrostatic InteractionsHydrogen Bond OrientationTarget-ligand Interactions
The structures of the noncovalent complex of human factor Xa (fXa) with four non-peptide inhibitors containing a central sulfonylpiperazinone scaffold have been determined to about 2.1 A resolution. Highly potent fXa inhibitors containing both neutral groups such as chlorobenzothiophene or chlorothiophene and basic groups such as benzamidine were shown to interact in the S1 pocket through the neutral group whereas the S4 pocket is occupied by the basic moiety. The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal role in the orientation of substituents, since there is a strong hydrogen bond between Gly219 of fXa and the carbonyl oxygen of the piperazine. This unique "reverse" binding mode is heretofore unreported in fXa and shows that electrostatic interactions in the S1 subsite are not an absolute requirement to maintain high affinity. Selectivity against other serine proteases can be readily explained in light of these structural results. It has opened up new prospects for designing fXa inhibitors with increased oral bioavailability.
11
The Entropic Cost of Bound Water in Crystals and Biomolecules
Jack D. Dunitz · Science · 1994 · 577 citations
Structure of Human Des(1-45) Factor Xa at 2·2 Å Resolution
K. Padmanabhan, K. Padmanabhan, A. Tulinsky et al. · Journal of Molecular Biology · 1993 · 392 citations
Quantum Engineering of Optical Nonlinearities
E. Rosencher, Andrea Fiore, B. Vinter et al. · Science · 1996 · 345 citations
X-ray Structure of Active Site-inhibited Clotting Factor Xa
Hans Brandstetter, Anja Kühne, Wolfram Bode et al. · Journal of Biological Chemistry · 1996 · 278 citations · Full text